DiscGenics treats 1st patient in degenerative disc disease clinical trial: 5 things to know

Mackenzie Garrity -   Print  |

DiscGenics principal investigator Domagoj Coric, MD, of Carolina Neurosurgery and Spine Associates in Charlotte, N.C., treated the first patient in the phase 1/phase 2 clinical trial of IDCT.

Here are five things to know.

1. The clinical trial is testing developing cell therapies for treating mild to moderate degenerative disc disease.

2. IDCT is an allogeneic, noninvasive cell therapy comprised of discogenic cells and a viscous scaffold carrier. The study is designed to evaluate safety and preliminary efficacy of IDCT at different dosage levels in patients with single-level, symptomatic lumbar degenerative disc disease.

3. DiscGenics plans to introduce the trial at 10 centers across the U.S. and enroll roughly 60 patients. Patients who meet criteria will be randomly divided into four treatment cohorts.

4. All patients will receive a single intradiscal injection of the assigned treatment into the lumbar intervertebral disc.

5. After the treatment, patients will be followed and evaluated for one year, with an one-year extension period.

More articles on biologics:
3 things to know about Organogenesis
Study: Single-injection durolane hylauronic acid safe, effective treatment for knee osteoarthritis
Who are the 14 major players in the global spine biologics market?

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers